Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0R5ZL
|
||||
Former ID |
DNC001252
|
||||
Drug Name |
S-(-)-sulpiride
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [1], [2], [3] | ||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C15H23N3O4S
|
||||
Canonical SMILES |
CCN1CCCC1CNC(=O)C2=C(C=CC(=C2)OC)S(=O)(=O)N
|
||||
InChI |
1S/C15H23N3O4S/c1-3-18-8-4-5-11(18)10-17-15(19)13-9-12(22-2)6-7-14(13)23(16,20)21/h6-7,9,11H,3-5,8,10H2,1-2H3,(H,17,19)(H2,16,20,21)
|
||||
InChIKey |
KRSITCLIUSFUOQ-UHFFFAOYSA-N
|
||||
CAS Number |
CAS 23672-07-3
|
||||
PubChem Compound ID | |||||
PubChem Substance ID | |||||
SuperDrug ATC ID |
N05AL01
|
||||
SuperDrug CAS ID |
cas=015676161
|
||||
Target and Pathway | |||||
Target(s) | D(2) dopamine receptor | Target Info | Antagonist | [1], [2], [3] | |
KEGG Pathway | Rap1 signaling pathway | ||||
cAMP signaling pathway | |||||
Neuroactive ligand-receptor interaction | |||||
Gap junction | |||||
Dopaminergic synapse | |||||
Parkinson's disease | |||||
Cocaine addiction | |||||
Alcoholism | |||||
PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
Dopamine receptor mediated signaling pathway | |||||
Nicotine pharmacodynamics pathway | |||||
Reactome | Dopamine receptors | ||||
G alpha (i) signalling events | |||||
WikiPathways | Hypothetical Network for Drug Addiction | ||||
Monoamine GPCRs | |||||
GPCRs, Class A Rhodopsin-like | |||||
Genes and (Common) Pathways Underlying Drug Addiction | |||||
GPCR ligand binding | |||||
GPCR downstream signaling | |||||
Nicotine Activity on Dopaminergic Neurons | |||||
References | |||||
REF 1 | D(2) dopamine receptors enable delta(9)-tetrahydrocannabinol induced memory impairment and reduction of hippocampal extracellular acetylcholine concentration. Br J Pharmacol. 2000 Jul;130(6):1201-10. | ||||
REF 2 | The treatment of Tourette's syndrome: current opinions. Expert Opin Pharmacother. 2002 Jul;3(7):899-914. | ||||
REF 3 | The effects of antipsychotic drugs on Fos protein expression in the prefrontal cortex: cellular localization and pharmacological characterization. Neuroscience. 1996 Jan;70(2):377-89. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.